Back to Search Start Over

ViaLase receives CE Mark for its ViaLase Laser, a femtosecond laser for glaucoma treatment

Source :
PharmaBiz. August 1, 2024
Publication Year :
2024

Abstract

ViaLase, Inc., a clinical-stage medical technology company focused on addressing unmet needs in the conventional glaucoma treatment paradigm, announced that it has received CE (Conformité Européenne) Mark approval in the [...]

Details

Language :
English
Database :
Gale General OneFile
Journal :
PharmaBiz
Publication Type :
Periodical
Accession number :
edsgcl.803410091